Viatris Inc. (VTRS)VTRSViatris Inc.

SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
4	Jul 1, 2026	Jul 1, 2026	View filing
4	Jul 1, 2026	Jul 1, 2026	View filing
8-K	Jul 1, 2026	Jul 1, 2026	View filing
4	Jun 26, 2026	Jun 26, 2026	View filing
8-K	Jun 18, 2026	Jun 18, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
424B5	Jun 15, 2026	Jun 15, 2026	View filing
FWP	Jun 12, 2026	Jun 12, 2026	View filing
424B5	Jun 12, 2026	Jun 12, 2026	View filing
8-K	May 15, 2026	May 15, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
SC 13G/A	May 5, 2026	May 5, 2026	View filing
8-K	May 4, 2026	May 4, 2026	View filing
SC 13G	Apr 30, 2026	Apr 30, 2026	View filing
4	Apr 16, 2026	Apr 16, 2026	View filing
ARS	Apr 2, 2026	Apr 2, 2026	View filing
DEFA14A	Apr 2, 2026	Apr 2, 2026	View filing
DEF 14A	Apr 2, 2026	Apr 2, 2026	View filing
SC 13G/A	Mar 27, 2026	Mar 27, 2026	View filing
4	Mar 24, 2026	Mar 24, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing
4	Mar 10, 2026	Mar 10, 2026	View filing

About Viatris Inc.

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Canonsburg, PA

30,000 employees

www.viatris.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Scott Andrew Smith

View full financials